Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer
AbstractIn some cases of human epidermal growth factor 2 (HER2)-negative breast cancer, including triple-negative breast cancer, HER2 expression is sporadically and strongly upregulated, a condition known asHER2 heterogeneity. We investigated the clinicopathological features of patients withHER2 heterogeneity in triple-negative breast cancers treated with neoadjuvant chemotherapy. Thirty-nine patients with triple-negative breast cancer who had undergone preoperative chemotherapy participated in this study. To assess forHER2 heterogeneity, we used dual in situ hybridization slides. We evaluated the association betweenHER2 h...
Source: Medical Molecular Morphology - April 15, 2024 Category: Molecular Biology Source Type: research
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
AbstractDespite major therapeutic advances for two decades, including the most recently approved anti-HER2 drugs, brain metastatic localizations remain the major cause of death for women with metastatic HER2 breast cancer. The main reason is the limited drug passage of the blood-brain barrier after intravenous injection and the significant efflux of drugs, including monoclocal antibodies, after administration into the cerebrospinal fluid. We hypothesized that this efflux was linked to the presence of a FcRn receptor in the blood-brain barrier. To overcome this efflux, we engineered two Fab fragments of trastuzumab, an anti...
Source: Experimental Hematology and Oncology - April 15, 2024 Category: Cancer & Oncology Source Type: research
Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy
CONCLUSIONS: HER2-positive breast cancer exhibited three distinct HR-specific subtypes with varying clinical manifestations and treatment responses. These findings suggest personalized treatment strategies considering ER and PR expression patterns, emphasizing the need for further investigations to unravel molecular traits underlying HER2-positive breast cancer with distinct HR expression patterns.PMID:38615482 | DOI:10.1016/j.breast.2024.103733 (Source: Breast)
Source: Breast - April 14, 2024 Category: Cancer & Oncology Authors: Haizhu Chen Xiujuan Gui Ziwei Zhou Fengxi Su Chang Gong Shunrong Li Wei Wu Nanyan Rao Qiang Liu Herui Yao Source Type: research
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial
CONCLUSIONS: First line metronomic chemotherapy for HER2 negative ABC had similar clinical activity and quite better tolerability than standard schedule and could be considered a further treatment option when chemotherapy is indicated.PMID:38615483 | DOI:10.1016/j.breast.2024.103725 (Source: Breast)
Source: Breast - April 14, 2024 Category: Cancer & Oncology Authors: Laura Orlando Evaristo Maiello Michele Orditura Anna Diana Giuliano Antoniol Maria Grazia Morritti Michele Aieta Mariangela Ciccarese Salvatore Pisconti Roberto Bordonaro Antonio Russo Antonio Febbraro Paola Schiavone Annamaria Quaranta Chiara Caliolo Dar Source Type: research
Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity
This study demonstrates that the combination of trastuzumab and MD-Fraction exerts a greater antitumor effect than trastuzumab alone by enhancing ADCC, CDCC, and CDC in HER2-positive breast cancer.PMID:38616114 | DOI:10.1248/bpb.b23-00802 (Source: Biological and Pharmaceutical Bulletin)
Source: Biological and Pharmaceutical Bulletin - April 14, 2024 Category: Drugs & Pharmacology Authors: Yuki Masuda Shizuka Yamashita Yoshiaki Nakayama Ryohei Shimizu Morichika Konishi Source Type: research
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial
CONCLUSIONS: First line metronomic chemotherapy for HER2 negative ABC had similar clinical activity and quite better tolerability than standard schedule and could be considered a further treatment option when chemotherapy is indicated.PMID:38615483 | DOI:10.1016/j.breast.2024.103725 (Source: Breast)
Source: Breast - April 14, 2024 Category: Cancer & Oncology Authors: Laura Orlando Evaristo Maiello Michele Orditura Anna Diana Giuliano Antoniol Maria Grazia Morritti Michele Aieta Mariangela Ciccarese Salvatore Pisconti Roberto Bordonaro Antonio Russo Antonio Febbraro Paola Schiavone Annamaria Quaranta Chiara Caliolo Dar Source Type: research
Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy
CONCLUSIONS: HER2-positive breast cancer exhibited three distinct HR-specific subtypes with varying clinical manifestations and treatment responses. These findings suggest personalized treatment strategies considering ER and PR expression patterns, emphasizing the need for further investigations to unravel molecular traits underlying HER2-positive breast cancer with distinct HR expression patterns.PMID:38615482 | DOI:10.1016/j.breast.2024.103733 (Source: Breast)
Source: Breast - April 14, 2024 Category: Cancer & Oncology Authors: Haizhu Chen Xiujuan Gui Ziwei Zhou Fengxi Su Chang Gong Shunrong Li Wei Wu Nanyan Rao Qiang Liu Herui Yao Source Type: research
Investigating the level of vitamin D receptor gene expression in two tumoral and healthy breast tissues in breast cancer patients and its association with prognostic factors
CONCLUSIONS: The expression level of VDR in healthy tissue was significantly higher than tumoral tissue. However, there was no significant relationship between VDR and tumor grade, HER2, ER, PR, LVI, LN, disease stage, age, and tumor size.PMID:38616231 | DOI:10.1186/s43046-024-00215-5 (Source: J Egypt Natl Canc In...)
Source: J Egypt Natl Canc In... - April 14, 2024 Category: Cancer & Oncology Authors: Maryam Bahador Marjan Saeedi Nejad Shahriar Dabiri Mohammad Hasan Larizadeh Maryam Fekri Soofiabadi Source Type: research
Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity
This study demonstrates that the combination of trastuzumab and MD-Fraction exerts a greater antitumor effect than trastuzumab alone by enhancing ADCC, CDCC, and CDC in HER2-positive breast cancer.PMID:38616114 | DOI:10.1248/bpb.b23-00802 (Source: Biological and Pharmaceutical Bulletin)
Source: Biological and Pharmaceutical Bulletin - April 14, 2024 Category: Drugs & Pharmacology Authors: Yuki Masuda Shizuka Yamashita Yoshiaki Nakayama Ryohei Shimizu Morichika Konishi Source Type: research
Investigating the level of vitamin D receptor gene expression in two tumoral and healthy breast tissues in breast cancer patients and its association with prognostic factors
CONCLUSIONS: The expression level of VDR in healthy tissue was significantly higher than tumoral tissue. However, there was no significant relationship between VDR and tumor grade, HER2, ER, PR, LVI, LN, disease stage, age, and tumor size.PMID:38616231 | DOI:10.1186/s43046-024-00215-5 (Source: J Egypt Natl Canc In...)
Source: J Egypt Natl Canc In... - April 14, 2024 Category: Cancer & Oncology Authors: Maryam Bahador Marjan Saeedi Nejad Shahriar Dabiri Mohammad Hasan Larizadeh Maryam Fekri Soofiabadi Source Type: research
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial
CONCLUSIONS: First line metronomic chemotherapy for HER2 negative ABC had similar clinical activity and quite better tolerability than standard schedule and could be considered a further treatment option when chemotherapy is indicated.PMID:38615483 | DOI:10.1016/j.breast.2024.103725 (Source: Breast)
Source: Breast - April 14, 2024 Category: Cancer & Oncology Authors: Laura Orlando Evaristo Maiello Michele Orditura Anna Diana Giuliano Antoniol Maria Grazia Morritti Michele Aieta Mariangela Ciccarese Salvatore Pisconti Roberto Bordonaro Antonio Russo Antonio Febbraro Paola Schiavone Annamaria Quaranta Chiara Caliolo Dar Source Type: research
Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy
CONCLUSIONS: HER2-positive breast cancer exhibited three distinct HR-specific subtypes with varying clinical manifestations and treatment responses. These findings suggest personalized treatment strategies considering ER and PR expression patterns, emphasizing the need for further investigations to unravel molecular traits underlying HER2-positive breast cancer with distinct HR expression patterns.PMID:38615482 | DOI:10.1016/j.breast.2024.103733 (Source: Breast)
Source: Breast - April 14, 2024 Category: Cancer & Oncology Authors: Haizhu Chen Xiujuan Gui Ziwei Zhou Fengxi Su Chang Gong Shunrong Li Wei Wu Nanyan Rao Qiang Liu Herui Yao Source Type: research
Maitake Beta-Glucan Enhances the Therapeutic Effect of Trastuzumab via Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity
This study demonstrates that the combination of trastuzumab and MD-Fraction exerts a greater antitumor effect than trastuzumab alone by enhancing ADCC, CDCC, and CDC in HER2-positive breast cancer.PMID:38616114 | DOI:10.1248/bpb.b23-00802 (Source: Biological and Pharmaceutical Bulletin)
Source: Biological and Pharmaceutical Bulletin - April 14, 2024 Category: Drugs & Pharmacology Authors: Yuki Masuda Shizuka Yamashita Yoshiaki Nakayama Ryohei Shimizu Morichika Konishi Source Type: research
Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial
CONCLUSIONS: First line metronomic chemotherapy for HER2 negative ABC had similar clinical activity and quite better tolerability than standard schedule and could be considered a further treatment option when chemotherapy is indicated.PMID:38615483 | PMC:PMC11021991 | DOI:10.1016/j.breast.2024.103725 (Source: Breast)
Source: Breast - April 14, 2024 Category: Cancer & Oncology Authors: Laura Orlando Evaristo Maiello Michele Orditura Anna Diana Giuliano Antoniol Maria Grazia Morritti Michele Aieta Mariangela Ciccarese Salvatore Pisconti Roberto Bordonaro Antonio Russo Antonio Febbraro Paola Schiavone Annamaria Quaranta Chiara Caliolo Dar Source Type: research
Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy
CONCLUSIONS: HER2-positive breast cancer exhibited three distinct HR-specific subtypes with varying clinical manifestations and treatment responses. These findings suggest personalized treatment strategies considering ER and PR expression patterns, emphasizing the need for further investigations to unravel molecular traits underlying HER2-positive breast cancer with distinct HR expression patterns.PMID:38615482 | DOI:10.1016/j.breast.2024.103733 (Source: Breast)
Source: Breast - April 14, 2024 Category: Cancer & Oncology Authors: Haizhu Chen Xiujuan Gui Ziwei Zhou Fengxi Su Chang Gong Shunrong Li Wei Wu Nanyan Rao Qiang Liu Herui Yao Source Type: research
